|
For more information please contact:
Investment Banking
James Antonopoulos
Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906
jantonopoulos@roth.com
Aparna Beeram
Vice President
(646) 358-1912
abeeram@roth.com
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
agurewitz@roth.com
Nazan Akdeniz
Senior Vice President
(949) 720-5740
nakdeniz@roth.com
Lou Ellis
Senior Vice President
(949) 720-5739
lellis@roth.com |
Transaction Information
Moleculin Biotech, Inc., (Nasdaq: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, has closed an underwritten public offering of an aggregate of 16,414,736 shares of common stock, which includes an additional 2,141,052 shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold at the public offering price of $4.75 per share, resulting in the gross proceeds for Moleculin Biotech of approximately $78 million. Moleculin Biotech intends to use the proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.
Roth Capital Partners acted as co-manager for the offering.
About Moleculin Biotech
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. For more information, please visit
www.moleculin.com.
(Source: Company Press Release | 02.03.21)
About Roth Capital Partners
Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and
their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading,
market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and
maintains offices throughout the U.S. For more information on ROTH, please visit
www.roth.com. |
|
Date of Announcement: 03.05.21
The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC
("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any
companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or
estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be
reproduced in any form without the express written permission of Roth. Copyright 2021. |
